Treatment of Kynurenin-producing Tumors with AhR Antagonists
Activation of the aryl hydrocarbon receptor (AHR) by environmental xenobiotic toxins has been implicated in a variety of cellular processes such as embryogenesis, transformation, tumorigenesis and inflammation. The TDO-AHR pathway is active in human brain tumors and associated with malignant progression and poor survival. As Kyn is produced during cancer progression and inflammation in the local microenvironment in amounts sufficient for activating the human AHR, these results can be used to develop a specific chemotherapy to manipulate AhR activated signal pathways in susceptible cancer cells. Using this mechanism more treatment opportunities can be used and different tumor types can be treated by AhR related drugs.
Further Information: PDF
Deutsches Krebsforschungszentrum DKFZ
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Why getting in touch with our ‘gerbil brain’ could help machines listen better
Macquarie University researchers have debunked a 75-year-old theory about how humans determine where sounds are coming from, and it could unlock the secret to creating a next generation of more…
Attosecond core-level spectroscopy reveals real-time molecular dynamics
Chemical reactions are complex mechanisms. Many different dynamical processes are involved, affecting both the electrons and the nucleus of the present atoms. Very often the strongly coupled electron and nuclear…
Free-forming organelles help plants adapt to climate change
Scientists uncover how plants “see” shades of light, temperature. Plants’ ability to sense light and temperature, and their ability to adapt to climate change, hinges on free-forming structures in their…
